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IL-15 and Psoriasis: Another Genetic 
Link to Th17?
James T. Elder1
Interleukin-15 (IL-15) is a pro-inflammatory cytokine expressed in sever-
al inflammatory disorders. Zhang et al. (2007, this issue) report a significant 
genetic association between IL-15 and psoriasis, which may involve increased 
stability of IL-15 mRNA. Among its several activities, IL-15 stimulates the expres-
sion of IL-17 by T-cells. Together with recent genetic and therapeutic evidence 
implicating IL-23, these findings suggest a genetic basis for Th17-mediated 
inflammation in psoriasis.
Journal of Investigative Dermatology (2007) 127, 2495–2497. doi:10.1038/sj.jid.5700855
In this issue of the Journal of 
Investigative Dermatology, Zhang and 
colleagues (2007) report an association 
between psoriasis and single-nucleo-
tide polymorphisms (SNPs) in the 
interleukin-15 (IL-15) gene, which is 
located on chromosomal band 4q31.2. 
The study follows a genome scan from 
the same laboratory implicating the 
4q28–31 region in Chinese families 
affected with psoriasis, which was 
recently confirmed in an indepen-
dent sample of Chinese families (Yan 
et al., 2007). This locus, which has 
been named psoriasis susceptibility 9 
(PSORS9), also came to light in a meta-
analysis of five genome-wide linkage 
studies (Sagoo et al., 2004). Other 
than PSORS1, the major psoriasis sus-
ceptibility locus located in the MHC, 
PSORS9 was the most strongly linked 
locus identified by the meta-analysis.
To investigate the IL-15 gene in pso-
riasis, Zhang and colleagues (2007) 
changed their research strategy from 
linkage to association. Linkage analy-
sis is the tracing of alleles at marker 
loci through families, with the precise 
identity of the alleles involved usu-
ally varying from family to family. In 
contrast, association analysis involves 
the comparison of the frequencies of 
specific alleles in cases vs. controls, 
with the identity of the allele involved 
being the same, even in unrelated indi-
viduals. In effect, the association strat-
egy treats an entire population as one 
large family that has been subjected to 
many recombination events over time. 
Because of this, only markers located 
very close to a disease gene (~50 kilo-
bases) will yield disease associations, 
whereas markers residing as far as 10 
megabases from the disease gene can 
be used to detect linkage. Although 
linkage analysis is the method of 
choice for Mendelian disorders, the 
association strategy is much more pow-
erful for the so-called “complex genetic 
disorders.” For the most part, these dis-
orders involve common genetic vari-
ants, which are common because they 
arose long ago (Risch and Merikangas, 
1996). Such genetic variants do not 
generally act alone—rather, they act 
in concert with other common genetic 
variants to provoke disease, and each 
individual variant is best thought of 
as a determinant of disease suscepti-
bility, rather than “the cause” of dis-
ease. The search for these common 
determinants of susceptibility is rap-
idly gaining momentum across a wide 
variety of common diseases, aided by 
the development of a dense map of 
human haplotypes (the HapMap) and 
microarray technology for SNP typing. 
Capable of typing an individual for up 
to a million SNPs, microarray technol-
ogy allows an unbiased search of the 
entire genome for disease associations. 
The major challenge of these studies 
is their expense, but genotyping costs 
continue to decrease and the number 
of such genome-wide association stud-
ies is increasing rapidly.
Sample size is a critical factor for a 
successful disease gene search via the 
association strategy. Zhang and col-
leagues (2007) collected a sample of 
632 unrelated psoriatic patients and 
485 healthy controls, a sample neither 
large nor small by today’s standards. 
The power of a given sample to detect 
associations depends on the disease 
prevalence, the disease allele frequen-
cy, the relative risk posed by possession 
of the variant, and the genetic model. 
Utilizing software available on the Web 
(Power Calculator for Genome Wide 
Association Studies, http://www.sph.
umich.edu/csg/abecasis/CaTS), it can 
be estimated that this sample has from 
29 to 52% power to detect a disease 
allele conferring the properties report-
ed in this study, depending on disease 
model (dominant 29%, additive 42%, 
multiplicative 52%). (These values 
were calculated for a relative risk of 
1.65 at a significance level of 0.00005, 
which are the values reported for the 
most strongly associated haplotype 
identified in this study.) Thus, it could 
be argued that, despite the positive 
results of this study, larger sample sizes 
may be needed to replicate this genetic 
effect. Certainly, replication is essential 
for validation of any association study 
in a complex genetic disorder.
To determine the optimal set of 
markers for typing, Zhang and col-
leagues (2007) sequenced the eight 
known exons of the IL-15 gene and 
their boundaries, as well as about 
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2,000 base pairs of the 5′ and 3′ flank-
ing regions, in 48 cases and 48 con-
trols. This effort identified 19 variants, 
of which 14 were already known and 
deposited in the SNP database. This 
illustrates the considerable power of 
the SNP database to identify SNPs by 
database searching, rather than labo-
rious sequencing, as has been neces-
sary in the past. They next determined 
the patterns of linkage disequilibrium 
within the IL-15 gene, allowing them to 
select a subset of 12 markers that best 
described the differences between indi-
viduals across the gene. Their result was 
very similar to that obtained by query-
ing the HapMap database for the Han 
Chinese population in Bejing, China, 
illustrating the power of existing data-
bases to identify optimal markers for 
genotyping. The most significantly asso-
ciated SNPs in this study were located 
in the 3′ untranslated region (3′-UTR) 
of the IL-15 gene. The most significant 
individual marker reached a P value 
of 0.00006 after correction for testing 
of 12 markers, with the rarer T allele 
conferring increased risk. Although the 
subject of correction for multiple test-
ing always provokes a lively debate, 
the correction factor used here is rea-
sonable given that there is already link-
age evidence for a gene in this region 
and that the markers used were not in 
linkage disequilibrium with each other. 
(A statistical purist might call for more 
stringent correction, because there are 
65 genes in the linkage interval (Yan 
et al., 2007).) Next, haplotypes were 
inferred, again with good statistical 
respect for the multiple testing issue. 
(Haplotypes are defined as the set of 
alleles at in a group of linked loci that 
are present on a single (haploid) chro-
mosome.) Reassuringly, these calcula-
tions revealed that the most strongly 
associated haplotype yielded P values 
similar to those obtained for the most 
strongly associated individual marker, 
and each of the two haplotypes car-
rying the rare allele (T) at that marker 
conferred increased risk.
Zhang and colleagues (2007) went 
on to begin to explore the functional 
role of the 3′-UTR by cloning differ-
ent variants of the 3′-UTR into a lucif-
erase reporter construct and trans-
fecting these constructs into Jurkat 
cells. Interestingly, the two haplotypes 
carrying the T allele yielded 34 to 53% 
higher levels of luciferase activity than 
did the most common, non-disease-
associated haplotype. Although the 
precise mechanism for this effect 
remains to be identified, there are 
numerous precedents for sequences in 
the 3′-UTR to control mRNA levels via 
elements that regulate RNA stability.
IL-15 is an excellent candidate for 
involvement in psoriasis. It has been 
implicated in several other inflamma-
tory disorders, including rheumatoid 
arthritis, diabetes, and pulmonary 
inflammation (McInnes and Gracie, 
2004). IL-15 has structural similarities 
with IL-2 and interacts with the β- and 
γ-chains of the IL-2 receptor, differing 
from IL-2 in that IL-15 interacts with a 
unique α-chain (IL15Rα) distinct from 
the IL2Rα, which recognizes IL-2. 
Keratinocytes express both IL-15 and 
IL15Rα, suggesting a mechanism for 
interaction with other immune and/or 
inflammatory cells via IL-15 and its 
receptor (McInnes and Gracie, 2004). 
Two studies have found overexpression 
of IL-15 in psoriatic lesions, albeit using 
different methods and producing some-
what different results (McInnes and 
Gracie, 2004). IL-15 is also a growth 
factor for CD8+ T-cells, which infiltrate 
the epidermis during the development 
of psoriatic lesions. IL-15 also triggers 
inflammatory cell recruitment, angio-
genesis, and production of other cyto-
kines implicated in the pathogenesis of 
psoriasis, including IFN-γ and TNF-α. 
A functional role for IL-15 in psoriasis 
was suggested by studies of psoriatic 
skin xenografted onto immunocompro-
mised mice. Injection of an antibody 
targeting IL-15 bound to its receptor led 
to pronounced reduction in the sever-
ity of psoriatic lesions, including reduc-
tions in epidermal hyperplasia, paraker-
atosis, and inflammatory cell infiltration 
(Villadsen et al., 2003). Thus, based on 
both genetic and functional data, IL-15 
is a prime candidate for involvement in 
the pathogenesis of psoriasis. Efforts to 
replicate the genetic findings are clearly 
in order and, if successful, should drive 
a major effort to explore the immuno-
logic functions of IL-15 in psoriasis.
After a long period of uncertainty, it 
would appear that the genetics of pso-
riasis are coming into focus with the 
identification of specific susceptibility 
genes. In addition to the IL-15 findings 
reported in this issue, HLA-Cw6 was 
identified as the likely disease allele 
at PSORS1 (Nair et al., 2006), and two 
studies identified associations between 
psoriasis and the SLC12A8 gene at the 
PSORS5 locus (3q21) (Huffmeier et 
al., 2005). Another recent study identi-
fied a strong association with the p40 
subunit of IL-23 (IL12B) and its recep-
tor (IL23R) (Cargill et al., 2007). The 
study by Cargill et al. was a replication 
of an association between psoriasis 
and IL12B reported in 2002 (Tsunemi 
et al., 2002) and, moreover, identi-
fied associations with IL12B in each of 
three independently ascertained case–
control samples, thus providing ample 
evidence for replication. In further 
support of an important role for IL-23 
in psoriasis, a monoclonal antibody 
targeting IL-23 was recently shown to 
be highly effective against psoriasis 
in a large double-blind, placebo-con-
trolled clinical trial (Krueger et al., 
2007). IL-23 has been implicated in 
supporting the proliferation and surviv-
al of the Th17 subset of CD4+ T-cells, 
which in turn was recently implicated 
in a variety of autoimmune disorders 
(Iwakura and Ishigame, 2006). The IL-
23 receptor has recently been impli-
cated in Crohn’s disease, which may 
explain the long-standing observation 
that psoriasis is eight times more com-
mon in Crohn’s disease patients than 
in controls. Interestingly, a recent study 
showed that IL-15 was even more 
effective than IL-23 in stimulating the 
production of IL-17 by human T-cell 
blasts (Hoeve et al., 2006). Assuming 
that the findings of Zhang et al. (2007) 
are confirmed in other populations, 
we can expect lively exploration of 
the cellular and biochemical path-
ways relating the genetic defects in IL-
15 and IL-23 to the function of Th17 
T-cell subset and subsequent tissue 
injury, not only in psoriasis but also in 
other inflammatory and autoimmune 
disorders. As genome-wide associa-
tion scan technology is increasingly 
applied to psoriasis, it would not be 
surprising if other genes residing along 
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Unraveling Mysteries of the 
Multifunctional Protein SPARC
Mizuho Fukunaga-Kalabis1 and Meenhard Herlyn1
The matricellular protein SPARC (secreted protein acidic and rich in cysteine) 
has diverse functions in melanoma cells. Because this secreted protein is pro-
duced not only in tumor cells but also in stromal cells, the question has been 
asked whether paracrine effects of stroma-derived SPARC contribute to mela-
noma progression. In this issue, Prada et al. (2007) begin to answer this question 
by demonstrating that SPARC produced by melanoma, but not stromal cells, is 
essential to regulate melanoma cell growth.
Journal of Investigative Dermatology (2007) 127, 2497–2498. doi:10.1038/sj.jid.5701050
The matricellular protein osteonec-
tin/SPARC (secreted protein acidic and 
rich in cysteine) has recently attracted 
the attention of cancer researchers as 
a novel regulator of tumor cell biology. 
SPARC is highly expressed in malig-
nant melanomas. Clinically, SPARC 
expression correlates with the aggres-
siveness of melanomas and the acquisi-
tion of metastatic phenotypes (Massi et 
al., 1999). SPARC has been shown to 
have three general functions: de-adhe-
sion, antiproliferation, and regulation 
of extracellular matrix (ECM) interac-
tions (Framson and Sage, 2004). Robert 
et al. (2006) demonstrated that SPARC 
represses expression of E-cadherin 
through up-regulation of Snail, lead-
ing to migratory and invasive behavior. 
The data strongly suggest that SPARC 
functionally induces epithelial–mes-
enchymal transition and contributes to 
transformation of melanocytes to mela-
noma. It was recently revealed that 
SPARC produced by melanoma cells 
regulates inflammatory processes to 
inhibit polymorphonuclear (PMN) leu-
kocyte recruitment and antitumor cyto-
toxic capacity (Alvarez et al., 2005), 
suggesting that SPARC contributes to 
cancer immunity.
Like other matricellular proteins, such 
as osteopontin or tenascin, SPARC plays 
diverse roles in melanoma development. 
One can speculate that SPARC functions 
differently at each stage of melanoma 
progression. Moreover, several studies 
have confirmed that SPARC promotes 
tumor progression in glioma (Schultz et 
al., 2002), while it reduces tumor activi-
ties in breast cancer (Koblinski et al., 
2005). These inconsistent observations 
suggest that regulation and function of 
SPARC are dependent on cellular con-
text. Additionally, because SPARC is not 
only expressed by tumor cells but also 
secreted by surrounding fibroblasts and 
endothelial cells, it has been questioned 
whether SPARC derived from tumor 
stromal cells plays any roles in tumor 
progression. Although two groups have 
tried to dissect the functions of host-
derived SPARC using SPARC null mice, 
their results showed some discrepancy. 
Both groups observed alterations in 
tumor-associated ECM components; 
however, one group demonstrated 
enhanced tumor growth in SPARC null 
mice (Brekken et al., 2003), whereas the 
other reported reduced tumor growth 
(Sangaletti et al., 2003).
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 Growth capacity of 
human melanoma cells 
depends on SPARC 
levels produced by 
the melanoma cells 
themselves.
